Spanish versions and validation of a series of rating scales and visual analogue scales to assess the subjective effects of cannabis.
Journal
International clinical psychopharmacology
ISSN: 1473-5857
Titre abrégé: Int Clin Psychopharmacol
Pays: England
ID NLM: 8609061
Informations de publication
Date de publication:
20 Nov 2023
20 Nov 2023
Historique:
medline:
20
11
2023
pubmed:
20
11
2023
entrez:
20
11
2023
Statut:
aheadofprint
Résumé
Cannabis is being legalized for medical and recreational purposes all around the world. However, the understanding of the psychological effects of cannabis is still limited, and it has been previously linked to mental disorders such as schizophrenia. Lately, new scales have been created and adapted to measure its psychological effects. The aim of this study is to create Spanish versions of some of these scales and test their psychometric characteristics. One hundred sixteen participants were recruited from Cannabis Social Clubs (CSC) in Barcelona, Spain. Participants under the effects of their own cannabis completed the Cannabis Experience Questionnaire-modified version (CEQ-mv), Addiction Research Centre Inventory-18 (ARCI-18), Psychotomimetic States Inventory (PSI) and Visual Analogue Scales (VAS). Questionnaires were completed in the CSC, providing a naturalistic setting for the study. Exploratory factor analysis and internal consistency were analyzed. PSI was reduced from a 6-factor to a 4-factor model with adequate to low reliability, ARCI-18 was reduced from a 3-factor to a 2-factor model with good reliability, and VAS were reduced from a 4-factor to a 3-factor model, also with good reliability. These questionnaires showed adequate reliability and can be used in future studies to test the subjective effects of cannabis in clinical and naturalistic settings.
Identifiants
pubmed: 37982285
doi: 10.1097/YIC.0000000000000498
pii: 00004850-990000000-00108
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
Références
Abush H, Ghose S, Van Enkevort EA, Clementz BA, Pearlson GD, Sweeney JA, et al. (2018). Associations between adolescent cannabis use and brain structure in psychosis. Psychiatry Res Neuroimaging 276:53–64.
Barkus EJ, Stirling J, Hopkins RS, Lewis S (2006). Cannabis-induced psychosis-like experiences are associated with high schizotypy. Psychopathology 39:175–178.
Bianconi F, Bonomo M, Marconi A, Kolliakou A, Stilo SA, Iyegbe C, et al. (2016). Differences in cannabis-related experiences between patients with a first episode of psychosis and controls. Psychol Med 46:995–1003.
Bidwell LC, Martin-Willett R, Karoly HC (2021). Advancing the science on cannabis concentrates and behavioural health. Drug Alcohol Rev 40:900–913.
Bouso JC, Pedrero-Pérez EJ, Gandy S, Alcázar-Córcoles MA (2016). Measuring the subjective: revisiting the psychometric properties of three rating scales that assess the acute effects of hallucinogens. Hum Psychopharmacol - Clin Exp 31:356–372.
Cavazos-Rehg PA, Sowles SJ, Krauss MJ, Agbonavbare V, Grucza R, Bierut L (2016). A content analysis of tweets about high-potency marijuana. Drug Alcohol Depend 166:100–108.
Cavazos-Rehg PA, Krauss MJ, Sowles SJ, Floyd GM, Cahn ES, Chaitan VL, et al. (2018). Leveraging user perspectives for insight into cannabis concentrates. Am J Drug Alcohol Abuse 44:628–641.
Chadwick VL, Rohleder C, Koethe D, Leweke FM (2020). Cannabinoids and the endocannabinoid system in anxiety, depression, and dysregulation of emotion in humans. Curr Opin Psychiatry 33:20–42.
Chan GCK, Hall W, Freeman TP, Ferris J, Kelly AB, Winstock A (2017). User characteristics and effect profile of Butane Hash Oil: an extremely high-potency cannabis concentrate. Drug Alcohol Depend 178:32–38.
Cloutier RM, Calhoun BH, Lanza ST, Linden-Carmichael AN (2022). Assessing subjective cannabis effects in daily life with contemporary young adult language. Drug Alcohol Depend 230:109205.
Curran HV, Freeman TP, Mokrysz C, Lewis DA, Morgan CJA, Parsons LH (2016). Keep off the grass? Cannabis, cognition and addiction. Nat Rev Neurosci 17:293–306.
Dellazizzo L, Potvin S, Giguère S, Dumais A (2022). Evidence on the acute and residual neurocognitive effects of cannabis use in adolescents and adults: a systematic meta-review of meta-analyses. Addiction (Abingdon, England) 117:1857–1870.
Di Forti M, Morgan C, Dazzan P, Pariante C, Mondelli V, Marques TR, et al. (2009). High-potency cannabis and the risk of psychosis. Br J Psychiatry 195:488–491.
Downey RG, King CV (1998). Missing data in likert ratings: a comparison of replacement methods. J Gen Psychol 125:175–191.
Ewusi Boisvert E, Bae D, Pang RD, Davis JP, Kelley-Quon LI, Barrington-Trimis JL, et al. (2020). Subjective effects of combustible, vaporized, and edible cannabis: Results from a survey of adolescent cannabis users. Drug Alcohol Depend 206:107716.
Fenn J, Tan C-S, George S (2020). Development, validation and translation of psychological tests. BJPsych Adv 26:306–315.
Freeman AM, Mokrysz C, Hindocha C, Lawn W, Morgan CJ, Freeman TP, et al. (2021). Does variation in trait schizotypy and frequency of cannabis use influence the acute subjective, cognitive and psychotomimetic effects of delta-9-tetrahydrocannabinol? A mega-analysis. J Psychopharmacol (Oxford, England) 35:804–813.
Green B, Kavanagh D, Young R (2003). Being stoned: a review of self-reported cannabis effects. Drug Alcohol Rev 22:453–460.
Hadar A, David J, Shalit N, Roseman L, Gross R, Sessa B, et al. (2022). The psychedelic renaissance in clinical research: a bibliometric analysis of three decades of human studies with psychedelics. J Psychoactive Drugs 55:1–10.
Haertzen CA (1974). An overview of addiction research center inventory scales (ARCI): an appendix and manual of scales. [U.S. Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration], National Institute on Drug Abuse.
Hudson R, Rushlow W, Laviolette SR (2018). Phytocannabinoids modulate emotional memory processing through interactions with the ventral hippocampus and mesolimbic dopamine system: implications for neuropsychiatric pathology. Psychopharmacology (Berl) 235:447–458.
Hunault CC, Böcker KBE, Stellato RK, Kenemans JL, de Vries I, Meulenbelt J (2014). Acute subjective effects after smoking joints containing up to 69 mg Δ9-tetrahydrocannabinol in recreational users: a randomized, crossover clinical trial. Psychopharmacology (Berl) 231:4723–4733.
Kleinloog D, Roozen F, De Winter W, Freijer J, Van Gerven J (2014). Profiling the subjective effects of Δ9-tetrahydrocannabinol using visual analogue scales. Int J Methods Psychiatr Res 23:245–256.
Kumar P, Mahato DK, Kamle M, Borah R, Sharma B, Pandhi S, et al. (2021). Pharmacological properties, therapeutic potential, and legal status of Cannabis sativa L.: an overview. Phytother Res 35:6010–6029.
Lamas X, Farré M, Llorente M, Camí J (1994). Spanish version of the 49-item short form of the Addiction Research Center Inventory (ARCI). Drug Alcohol Depend 35:203–209.
Lundahl LH, Greenwald MK (2016). Magnitude and duration of cue-induced craving for marijuana in volunteers with cannabis use disorder. Drug Alcohol Depend 166:143–149.
Mason OJ, Morgan CJM, Stefanovic A, Curran HV (2008). The psychotomimetic states inventory (PSI): measuring psychotic-type experiences from ketamine and cannabis. Schizophr Res 103:138–142.
Mason O, Morgan CJA, Dhiman SK, Patel A, Parti N, Patel A, et al. (2009). Acute cannabis use causes increased psychotomimetic experiences in individuals prone to psychosis. Psychol Med 39:951–956.
Morgan CJA, Gardener C, Schafer G, Swan S, Demarchi C, Freeman TP, et al. (2012). Sub-chronic impact of cannabinoids in street cannabis on cognition, psychotic-like symptoms and psychological well-being. Psychol Med 42:391–400.
Obradors-Pineda A, Bouso J-C, Parés-Franquero O, Romaní J-O (2021). Harm reduction and cannabis social clubs: Exploring their true potential. Int J Drug Policy 97:103358.
Okey SA, Meier MH (2020). A within-person comparison of the subjective effects of higher vs. lower-potency cannabis. Drug Alcohol Depend 216:108225.
Parés-Franquero O, Jubert-Cortiella X, Olivares-Gálvez S, Díaz-Castellano A, Jiménez-Garrido DF, Bouso JC (2019). Use and habits of the protagonists of the story: cannabis social clubs in barcelona. J Drug Issues 49:607–624.
R Core Team (2021). R: A language and environment for statistical computing. R Foundation for Statistical Computing. Vienna: Austria. https://www.R-project.org/.
Ransing R, de la Rosa PA, Pereira-Sanchez V, Handuleh JIM, Jerotic S, Gupta AK, et al. (2022). Current state of cannabis use, policies, and research across sixteen countries: cross-country comparisons and international perspectives. Trends Psychiatry Psychother 44(suppl 1). http://www.scielo.br/j/trends/a/DpJpXb8SQrZLKxGWFphNbwp/abstract/?lang=en. [Accessed 16 August 2022].
Rodgers J, Buchanan T, Scholey AB, Heffernan TM, Ling J, Parrott A (2001). Differential effects of Ecstasy and cannabis on self-reports of memory ability: a web-based study. Hum Psychopharmacol 16:619–625.
Sainz-Cort A, Jimenez-Garrido D, Muñoz-Marron E, Viejo-Sobera R, Heeroma J, Bouso JC (2021). Opposite roles for cannabidiol and δ-9-tetrahydrocannabinol in psychotomimetic effects of cannabis extracts: a naturalistic controlled study. J Clin Psychopharmacol 41:561–570.
Sainz-Cort A, Jimenez-Garrido D, Muñoz-Marron E, Viejo-Sobera R, Heeroma J, Bouso JC (2022). The effects of cannabidiol and δ-9-tetrahydrocannabinol in social cognition: a naturalistic controlled study. Cannabis Cannabinoid Res.
Schubart CD, Sommer IEC, van Gastel WA, Goetgebuer RL, Kahn RS, Boks MPM (2011). Cannabis with high cannabidiol content is associated with fewer psychotic experiences. Schizophr Res 130:216–221.
Ventura J, Nuechterlein KH, Subotnik KL, Gutkind D, Gilbert EA (2000). Symptom dimensions in recent-onset schizophrenia and mania: a principal components analysis of the 24-item Brief Psychiatric Rating Scale. Psychiatry Res 97:129–135.
Waskow IE, Olsson JE, Salzman C, Katz MM (1970). Psychological effects of tetrahydrocannabinol. Arch Gen Psychiatry 22:97–107.
Weil AT, Zinberg NE, Nelsen JM (1968). Clinical and psychological effects of marihuana in man. Science (New York, N.Y.) 162:1234–1242.
Xiao KB, Grennell E, Ngoy A, George TP, Le Foll B, Hendershot CS, et al. (2023). Cannabis self-administration in the human laboratory: a scoping review of ad libitum studies. Psychopharmacology (Berl) 240:1393–1415.